7:30 am / August 16, 2018 APR – JUN Net sales increased by 52% to SEK 55.6m (36.6). Adjusted for currency exchange rate effects the increase was 53% Operating profit increased to SEK 21.7m (11.0). Adjusted operating profit* also increased to SEK 21.7m (11.5) Operating profit inclu... read more

Company announcement, Helsinki, 16 August 2018 at 9:00 am Highlights, January – June 2018 Nexstim delivered its first Navigated Brain Therapy (NBT®) system in the US for the treatment of Major Depressive Disorder (MDD) following Nexstim's successful launch of the SmartFocusTM TMS technology... read more

Lund, Sweden, 18:00 CET, 16 August 2018 - BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that its antibiotic-eluting product CERAMENT G has been approved by Health Canada. CERAMENT G is the first and only CE-marked gentamicin-eluting injectab... read more

Oslo, Norway, 15 August 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will announce its second quarter and first half year 2018 results on Thursday, 23 August 2018. A presentation by Targovax's management to... read more

DUBLIN, Ireland and TREVOSE, Pa., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has terminated the public offering of ordinary shares previously announced on August 14, 2018.  The termination results from an assessment ... read more